5-year head & neck cancer survival increased from 45% to 73% in cel-sci's target population, cutting risk of death in half, as presented at leading cancer conference esmo 2023

Vienna, va.--(business wire)---- $cvm #esmo2023--5-year head & neck cancer survival increased from 45% to 73% in cel-sci's target population, as presented at leading cancer conference esmo 2023.
CVM Ratings Summary
CVM Quant Ranking